medigraphic.com
Revista Médica Sinergia

2019, Number 05

<< Back Next >>

Revista Médica Sinergia 2019; 4 (05)

Sarcopenia: integrated care approaches for older people

Rojas BC, Buckcanan VA, Benavides JG

Language: Spanish
References: 18
Page: 24-34
PDF size: 314.80 Kb.


ABSTRACT

Sarcopenia is an age related musculoeskeletal disease with loss of the muscular mass and its function. It is a pathology with great prevalence among the elderly. The etiology is multifactorial where nutrition, life style and hormones have an influence. Screenig is recomended on all adults at age of 65 years or older with the SARCF questionnaire. The diagnosis is probable if there is a loss on muscle strenght demonstrated on hand grip or a chair stand test. Diagnosis is made when you add a test that shows low muscle mass (DXA is the recommendation) o low muscle quality. The severe cases are the ones that present with a gait speed test below 0.8 meters/seg. Actually, there is no drug aproved for its use, so management is based on resistance trainig and a higher protein intake.


REFERENCES

  1. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The journal of nutrition, health & aging. 2018 Nov 22; 22(10): 1148-1161. https://doi.org/10.1007/s12603-018-1139-9

  2. Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arai H, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and Ageing. 2014 09 21; 43(6): 748-759. https://doi.org/10.1093/ageing/afu115

  3. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. Journal of Cachexia, Sarcopenia and Muscle. 2016 Oct 17; 7(5): 512-514. https://doi.org/10.1002/jcsm.12147

  4. Dhillon RJ, Hasni S. Pathogenesis and Management of Sarcopenia. Clinics in Geriatric Medicine. 2017 02; 33(1): 17-26. https://doi.org/10.1016/j.cger.2016.08.002

  5. Woo J. Sarcopenia. Clinics in Geriatric Medicine. 2017 08; 33(3): 305-314. https://doi.org/10.1016/j.cger.2017.02.003.

  6. Yu J. The etiology and exercise implications of sarcopenia in the elderly. International Journal of Nursing Sciences. 2015 06; 2(2): 199-203. https://doi.org/10.1016/j.ijnss.2015.04.010

  7. Calvani R, Marini F, Cesari M, Tosato M, Anker SD, et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. Journal of Cachexia, Sarcopenia and Muscle. 2015 07 07; 6(4): 278-286.https://doi.org/10.1002/jcsm.12051

  8. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2018 09 24; 48(1): 16-31. https://doi.org/10.1093/ageing/afy169

  9. Malmstrom TK, Morley JE. SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association. 2013 08; 14(8): 531- 532. https://doi.org/10.1016/j.jamda.2013.05.018

  10. Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatrics. 2016 Oct 05; 16: 170. https://doi.org/10.1186/s12877-016-0349-4

  11. Lee D, Shook RP, Drenowatz C, Blair SN. Physical activity and sarcopenic obesity: definition, assessment, prevalence and mechanism. Future Science OA. 2016 09; 2(3): FSO127. https://doi.org/10.4155/fsoa-2016- 0028

  12. Yarasheski KE. Exercise, Aging, and Muscle Protein Metabolism. The Journals of Gerontology Series A. 2003 Oct 01; 58(10): M918-M922. https://doi.org/10.1093/gerona/58.10.m918

  13. Roth SM, Ferrell RF, Hurley BF. Strength training for the prevention and treatment of sarcopenia. The Journal of Nutrition Health and Aging. 2000; 4(3): 143-155. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10936901

  14. Phillips SM, Chevalier S, Leidy HJ. Protein “requirements” beyond the RDA: implications for optimizing health. Applied Physiology, Nutrition, and Metabolism. 2016 05; 41(5): 565- 572. https://doi.org/10.1139/apnm-2015-0550

  15. Stewart Coats AJ, Srinivasan V, Surendran J, Chiramana H, Vangipuram SRKG, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:. Journal of Cachexia, Sarcopenia and Muscle. 2011 Oct 16; 2(4): 201- 207. https://doi.org/10.1007/s13539-011-0046-2

  16. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, et al. Losartan Restores Skeletal Muscle Remodeling and Protects Against Disuse Atrophy in Sarcopenia. Science Translational Medicine. 2011 05 11; 3(82): 82ra37-82ra37.https://doi.org/10.1126/scitranslmed.3002227

  17. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. The Lancet. 2013 03; 381(9868): 752-762. https://doi.org/10.1016/s0140-6736(12)62167-9

  18. Waters DL, Baumgartner RN. Sarcopenia and Obesity. Clinics in Geriatric Medicine. 2011 08; 27(3): 401- 421.https://doi.org/10.1016/j.cger.2011.03.007




2020     |     www.medigraphic.com